Literature DB >> 9506210

The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome.

N S Rote1, E Vogt, G DeVere, A R Obringer, A K Ng.   

Abstract

PROBLEM: The antiphospholipid (aPL) antibody syndrome is characterized by severe pregnancy complications, the cause of which remains unknown. We hypothesized that the placental trophoblast is a target for aPLs. METHOD OF STUDY: The effects of monoclonal aPLs on trophoblast function, including the invasion of JAR into matrigel-coated filters and the effects of annexin V expression on BeWo, were investigated using choriocarcinoma models.
RESULTS: aPLs against phosphatidylserine (PS) significantly (P < 0.001) decreased the migration of JAR across the membrane. In the annexin V studies, undifferentiated BeWo did not express surface annexin V. After differentiation, BeWo expressed surface annexin V, which was removed in the presence of aPLs, resulting in increased binding of prothrombin.
CONCLUSIONS: PS is expressed on the trophoblast surface during differentiation and invasion of extracellular matrix. Our data suggest that aPLs against PS can directly affect trophoblast function by limiting the depth of decidual invasion and by concurrently creating a procoagulant surface on trophoblast exposed to the maternal circulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506210     DOI: 10.1111/j.1600-0897.1998.tb00344.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  11 in total

Review 1.  Pathogenic role of antiphospholipid antibodies.

Authors:  J E Salmon; P G de Groot
Journal:  Lupus       Date:  2008-05       Impact factor: 2.911

2.  Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I.

Authors:  N Di Simone; P L Meroni; N de Papa; E Raschi; D Caliandro; C S De Carolis; M A Khamashta; T Atsumi; G R Hughes; G Balestrieri; A Tincani; P Casali; A Caruso
Journal:  Arthritis Rheum       Date:  2000-01

Review 3.  Pros and cons for C4d as a biomarker.

Authors:  Danielle Cohen; Robert B Colvin; Mohamed R Daha; Cinthia B Drachenberg; Mark Haas; Volker Nickeleit; Jane E Salmon; Banu Sis; Ming-Hui Zhao; Jan A Bruijn; Ingeborg M Bajema
Journal:  Kidney Int       Date:  2012-02-01       Impact factor: 10.612

Review 4.  Autoantibodies and coagulation in reproductive medicine.

Authors:  Hidehiko Matsubayashi
Journal:  Reprod Med Biol       Date:  2009-07-18

5.  Antiphospholipid antibodies associated with implantation failure after IVF/ET.

Authors:  C B Coulam; B D Kaider; A S Kaider; P Janowicz; R G Roussev
Journal:  J Assist Reprod Genet       Date:  1997-11       Impact factor: 3.412

6.  Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro.

Authors:  N Di Simone; E Raschi; C Testoni; R Castellani; M D'Asta; T Shi; S A Krilis; A Caruso; P L Meroni
Journal:  Ann Rheum Dis       Date:  2004-07-15       Impact factor: 19.103

7.  Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation.

Authors:  Jane E Salmon; Guillermina Girardi
Journal:  Trans Am Clin Climatol Assoc       Date:  2007

Review 8.  Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss.

Authors:  Pier Luigi Meroni; Maria Gerosa; Elena Raschi; Silvia Scurati; Claudia Grossi; Maria O Borghi
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 9.  Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation.

Authors:  Jane E Salmon; Guillermina Girardi
Journal:  J Reprod Immunol       Date:  2007-04-05       Impact factor: 4.054

10.  Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction.

Authors:  Guillermina Girardi; Dmitry Yarilin; Joshua M Thurman; V Michael Holers; Jane E Salmon
Journal:  J Exp Med       Date:  2006-08-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.